Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes
Andreana Foresta, Luisa Ojeda‐Fernández, Giulia Macaluso, Maria Carla Roncaglioni, Mauro Tettamanti, Ida Fortino, Olivia Leoni, Stefano Genovese, Marta Baviera
Topics & Concepts
Dipeptidyl peptidase-4MedicineGlucagon-like peptide-1Coronavirus disease 2019 (COVID-19)PharmacologyGlucagon-like peptide 1 receptorReceptor2019-20 coronavirus outbreakDipeptidyl peptidaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VildagliptinInternal medicineEndocrinologyDiabetes mellitusEnzymeType 2 diabetesBiochemistryAgonistVirologyInfectious disease (medical specialty)DiseaseBiologyOutbreakCOVID-19 Clinical Research StudiesDiabetes Treatment and ManagementSARS-CoV-2 and COVID-19 Research